Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

1. Rugo, H.S.
2. Bardia, A.
3. Marmé, F.
4. Cortés, J.
5. Schmid, P.
6. Loirat, D.
7. Trédan, O.
8. Ciruelos, E.
9. Dalenc, F.
10. Gómez Pardo, P.
11. Jhaveri, K.L.
12. Delaney, R.
13. Valdez, T.
14. Wang, H.
15. Motwani, M.
16. Yoon, O.K.
17. Verret, W.
18. Tolaney, S.M.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1016/S0140-6736(23)01245-X GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus